2137.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 16:08):

Stats
今日成交量	2.81M
平均成交量	4.17M
市值	926.64M
EPS	HKD0 ( 2024-03-25 )
下一个收益日期	( HKD0 ) 2024-06-25
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-4.88
ATR14	HKD0.00700 (0.56%)

音量相关性

長: -0.15 (neutral)

短: 0.48 (neutral)

Signal:(38.852) Neutral

Brii Biosciences Limited 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Brii Biosciences Limited 相关性 - 货币/商品

0.07
( neutral )

-0.09
( neutral )

0.00
( neutral )

0.34
( neutral )

-0.03
( neutral )

-0.80
( strong negative )

Brii Biosciences Limited 财务报表

Annual	2023
营收:	HKD617 000
毛利润:	HKD55.89M (9 058.51 %)
EPS:	HKD-0.240

FY	2023
营收:	HKD617 000
毛利润:	HKD55.89M (9 058.51 %)
EPS:	HKD-0.240

FY	2022
营收:	HKD51.63M
毛利润:	HKD51.63M (100.00 %)
EPS:	HKD-0.630

FY	2021
营收:	HKD0.00
毛利润:	HKD0.00 (0.00 %)
EPS:	HKD-5.90

Financial Reports:

No articles found.

Brii Biosciences Limited

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.